Next Article in Journal
Recent Advances in Proteomic Studies of Adipose Tissues and Adipocytes
Next Article in Special Issue
An Epigenetic Regulator: Methyl-CpG-Binding Domain Protein 1 (MBD1)
Previous Article in Journal
tRNA Biology in Mitochondria
Previous Article in Special Issue
Tumor Progression Locus 2 (Tpl2) Kinase as a Novel Therapeutic Target for Cancer: Double-Sided Effects of Tpl2 on Cancer
Open AccessReview

Roles of Ubiquitination and SUMOylation on Prostate Cancer: Mechanisms and Clinical Implications

Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN 37208, USA
*
Author to whom correspondence should be addressed.
Academic Editor: William Chi-Shing Cho
Int. J. Mol. Sci. 2015, 16(3), 4560-4580; https://doi.org/10.3390/ijms16034560
Received: 14 January 2015 / Revised: 9 February 2015 / Accepted: 12 February 2015 / Published: 27 February 2015
(This article belongs to the Collection Advances in Molecular Oncology)
The initiation and progression of human prostate cancer are highly associated with aberrant dysregulations of tumor suppressors and proto-oncogenes. Despite that deletions and mutations of tumor suppressors and aberrant elevations of oncogenes at the genetic level are reported to cause cancers, emerging evidence has revealed that cancer progression is largely regulated by posttranslational modifications (PTMs) and epigenetic alterations. PTMs play critical roles in gene regulation, cellular functions, tissue development, diseases, malignant progression and drug resistance. Recent discoveries demonstrate that ubiquitination and SUMOylation are complicated but highly-regulated PTMs, and make essential contributions to diseases and cancers by regulation of key factors and signaling pathways. Ubiquitination and SUMOylation pathways can be differentially modulated under various stimuli or stresses in order to produce the sustained oncogenic potentials. In this review, we discuss some new insights about molecular mechanisms on ubiquitination and SUMOylation, their associations with diseases, oncogenic impact on prostate cancer (PCa) and clinical implications for PCa treatment. View Full-Text
Keywords: posttranslational modifications; ubiquitination; SUMOylation; prostate cancer posttranslational modifications; ubiquitination; SUMOylation; prostate cancer
Show Figures

Figure 1

MDPI and ACS Style

Chen, Z.; Lu, W. Roles of Ubiquitination and SUMOylation on Prostate Cancer: Mechanisms and Clinical Implications. Int. J. Mol. Sci. 2015, 16, 4560-4580.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop